Inogen, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
January 10, 2023 at 08:05 am EST
Share
Inogen, Inc. provided preliminary revenue guidance for the fourth quarter and full year ended December 31, 2022. The company estimated preliminary, unaudited total revenue in the fourth quarter of 2022 to be in the range of $87.5 million to $88.5 million, representing year-over-year growth of 14.5% to 15.8%.
Full year 2022 total preliminary, unaudited revenue is expected to be in the range of $376.7 million to $377.7 million, representing year-over-year growth of 5.2% to 5.5%.
Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. The Company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One systems reduces patients' reliance on stationary concentrators and oxygen compressed gas tanks. Its Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5 and Rove 6 consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers. It also offers Simeox, which is an airway clearance device.